Human nuclear factor-κB p65,NF-κB p65 ELISA Kit

Code CSB-E08787h
See More Details 24T ELISA kits trial application
Product Type ELISA Kit
Size 96T,5×96T,10×96T
Uniprot No. Q04206
Lead Time 3-5 working days
Abbreviation RELA
Protein Biological Process 1 Immunity
Target Name v-rel reticuloendotheliosis viral oncogene homolog A (avian)
Alias MGC131774, NFKB3, p65, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3|v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene
Species Homo sapiens (Human)
Protein Biological Process 3 Host-virus interaction
Sample Types serum, plasma, tissue homogenates
Detection Range 47 pg/mL-3000 pg/mL
Sensitivity 11.75 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Immunology
Protocol
Protocol may be improved. Please feel free to contact CUSABIO product specialist to obtain the latest version.
Assay Principle quantitative
Measurement Sandwich
HGNC 9955
RGD 727889
MGI 103290
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human NF-κB p65 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:1Average %88
Range %83-92
1:2Average %101
Range %95-104
1:4Average %102
Range %98-105
1:8Average %95
Range %90-98
Recovery
The recovery of human NF-κB p65 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9389-96
EDTA plasma (n=4)9591-98
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
30002.751 2.732 2.742 2.618
15001.966 1.876 1.921 1.797
7501.356 1.344 1.350 1.226
3750.790 0.777 0.784 0.660
187.50.421 0.403 0.412 0.288
940.323 0.312 0.318 0.194
470.209 0.196 0.203 0.079
00.125 0.123 0.124  
References
Still Have Questions? Leave a Message or Start an on-line Chat
Function NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells
Involvement in disease A chromosomal aberration involving C11orf95 is found in more than two-thirds of supratentorial ependymomas. Translocation with C11orf95 produces a C11orf95-RELA fusion protein. C11orf95-RELA translocations are potent oncogenes that probably transform neural stem cells by driving an aberrant NF-kappa-B transcription program (PubMed:24553141).
Subcellular Location Nucleus, Cytoplasm
Database Links

HGNC: 9955

OMIM: 164014

KEGG: hsa:5970

STRING: 9606.ENSP00000384273

UniGene: Hs.502875

Pathway cAMP signaling pathway
Chemokine signaling pathway
HIF-1 signaling pathway
MAPK signaling pathway
PI3K-Akt signaling pathway
NF-kappa B signaling pathway
TNF signaling pathway
Apoptosis
Cellular senescence
Ras signaling pathway
B cell receptor signaling pathway
IL-17 signaling pathway
NOD-like receptor signaling pathway
Osteoclast differentiation
T cell receptor signaling pathway
Th1 and Th2 cell differentiation
Th17 cell differentiation
Toll-like receptor signaling pathway
Adipocytokine signaling pathway
AGE-RAGE signaling pathway in diabetic complications
Sphingolipid signaling pathway
Neurotrophin signaling pathway

Related Products

RELA Antibodies

RELA Antibodies for Human

RELA Antibodies for Homo sapiens (Human)

RELA Antibodies for

RELA Proteins

RELA Proteins for Homo sapiens (Human)

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved.